Harmony Biosciences names Glenn Reicin CFO as Sandip Kapadia steps down
Harmony Biosciences said CFO Sandip Kapadia stepped down effective April 14, 2026, to pursue other career opportunities, and named Glenn Reicin as his successor effective the same day. The company also reiterated its 2026 net product revenue guidance of $1.0 to $1.04 billion, so the change does not come with a guidance change.
Key points
- Sandip Kapadia left the CFO role effective April 14, 2026; his separation agreement provides severance under his existing employment and award agreements, in exchange for a release of claims.
- Glenn Reicin, age 61, was appointed CFO effective April 14, 2026; he was CFO at Eccogene from October 2024 to October 2025.
- Reicin's employment agreement sets a $500,000 annual base salary, a target bonus of 50% of base salary, and an option award with a $3,000,000 grant date fair value vesting over four years.
- Harmony reiterated its 2026 net product revenue guidance of $1.0 to $1.04 billion, primarily from WAKIX sales.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.